The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.

The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year ...

Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s ...

Based on RBA exchange rate of 1 USD = 1.61 AUD as at 28 th February 2025. [2] Fresh Leaf Analytics, Australian Medicinal Cannabis Market, H1 2021.

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...